2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z

Abstract Number: 60

Paediatric Arthritis Rehabilitation Exercise Study
Abstract Number: 22

Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis
Abstract Number: 1

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Abstract Number: 63

Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
Abstract Number: 91

Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height
Abstract Number: 40

Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
Abstract Number: 99

PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS
Abstract Number: 79

Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
Abstract Number: 31

Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Abstract Number: 84

Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Abstract Number: 78

Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
Abstract Number: 159

Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center
Abstract Number: 81

Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee
Abstract Number: 122

Presenting Manifestations of Amplified Musculoskeletal Pain Syndrome in Males versus Females
Abstract Number: 13

Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis
Abstract Number: 56

Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis

Jump to: View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].